443 related articles for article (PubMed ID: 18353510)
1. Assessing vaccine potency using TCRmimic antibodies.
Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
[TBL] [Abstract][Full Text] [Related]
2. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
3. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
[TBL] [Abstract][Full Text] [Related]
4. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
[TBL] [Abstract][Full Text] [Related]
5. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
6. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.
Verma B; Neethling FA; Caseltine S; Fabrizio G; Largo S; Duty JA; Tabaczewski P; Weidanz JA
J Immunol; 2010 Feb; 184(4):2156-65. PubMed ID: 20065111
[TBL] [Abstract][Full Text] [Related]
7. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
[TBL] [Abstract][Full Text] [Related]
9. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
[TBL] [Abstract][Full Text] [Related]
12. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
[TBL] [Abstract][Full Text] [Related]
13. [Immune responses of dendritic cells after loaded with cytotoxicity T lymphocyte epitope based peptide of human alpha-fetoprotein (hAFP)].
Guo J; Cai M; Wei D; Qin L; Huang J; Wang X
Zhonghua Gan Zang Bing Za Zhi; 2002 Jun; 10(3):178-80. PubMed ID: 12113671
[TBL] [Abstract][Full Text] [Related]
14. Intracellular delivery of major histocompatibility complex class I-binding epitopes: dendritic cells loaded and matured with cationic peptide/poly(I:C) complexes efficiently activate T cells.
Haenssle HA; Riedl P; Buhl T; Schardt A; Rosenberger A; Schön MP; Schirmbeck R
Exp Dermatol; 2010 Jan; 19(1):19-28. PubMed ID: 19758325
[TBL] [Abstract][Full Text] [Related]
15. Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody.
Bernardeau K; Gouard S; David G; Ruellan AL; Devys A; Barbet J; Bonneville M; Chérel M; Davodeau F
Eur J Immunol; 2005 Oct; 35(10):2864-75. PubMed ID: 16163672
[TBL] [Abstract][Full Text] [Related]
16. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.
Cohen CJ; Denkberg G; Lev A; Epel M; Reiter Y
J Mol Recognit; 2003; 16(5):324-32. PubMed ID: 14523945
[TBL] [Abstract][Full Text] [Related]
17. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
18. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide.
Nakahara S; Tsunoda T; Baba T; Asabe S; Tahara H
Cancer Res; 2003 Jul; 63(14):4112-8. PubMed ID: 12874015
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
